As Russian drug-makers surge to keep pace with Western pharma companies in the race for a COVID-19 vaccine, Russia has derived results from a late stage human trial on their own candidate, Sputnik-V. Their sample size of 20 participants was far smaller than Pfizer’s 94, yielding a 92% efficacy rate which was said to be “hard to interpret” by many experts. Like Pfizer, the Russian Direct Investment Fund, who is backing the development of Sputnik-V, says it will be continuing the analysis and testing process for another six months. While some skepticism has been received by Russia from health officials elsewhere, nevertheless they pan to proceed into “Phase 3” of their clinical trial.
Read more here.
More on: News Regulatory